Post by
lonc17 on Jun 22, 2023 4:56pm
Precision Promise
Okay, this is a big deal. There is tons of informaiton out there re this trial, but the most significant points I can find are these:
1. I believe the non-profit PanCAN will be funding and running this - ONC has been invited as an extedened arm of the trial and their cost will be supply only.
2. Only 175 patients necessary for registration approval.
3. We're still years away due to the OS endpoint but today's news is equivalent to a Big Pharma stepping up and partnerning with ONC for pancreatic cancer.
IMO, we're less than one month away from a complete buyout of ONC by some pharma.
Good news, congrats.
https://aacrjournals.org/cancerres/article/81/22_Supplement/PO-050/670425/Abstract-PO-050-Precision-Promise-PrP-An-adaptive
Comment by
Noteable on Jun 22, 2023 8:43pm
The median overall survival is for a pancreatic cancer patient 9.3 months. So the PANCAN Precision Promise Phase 3 with pelareorep should move very quickly to determine OS.
Comment by
Noteable on Jun 22, 2023 8:44pm
Should read: The median overall survival for a pancreatic cancer patient is 9.3 months.